Apixaban Evaluation of Interrupted Or Uninterrupted Anticoagulation for Ablation of Atrial Fibrillation
Status:
Completed
Trial end date:
2017-04-01
Target enrollment:
Participant gender:
Summary
The purpose of the prospective, randomized cohort in this study is to assess the safety and
efficacy of 2 apixaban treatment strategies (uninterrupted versus interrupted) in subjects
planned to undergo catheter ablation for the treatment of non-valvular atrial fibrillation
(NVAF).
Simultaneously, a retrospective cohort of 300 warfarin-treated individuals, identified by
chart review, who are matched to the prospective randomized subjects, will be identified. The
purpose of the retrospective warfarin cohort is to compare the efficacy and safety of
warfarin(the current clinical practice) to that of apixaban (uninterrupted, interrupted,
combined uninterrupted and interrupted).
Phase:
Phase 4
Details
Lead Sponsor:
Baim Institute for Clinical Research Harvard Clinical Research Institute